German pharma company Fresenius Kabi has launched its severe hypothyroidism treatment -Levothyroxine Sodium Injection Solution in 100 mcg per 5 mL, 200 mcg per 5 mL and 500 mcg per 5 mL single-dose vials in the US.

The Levothyroxine Sodium Injection is the first-and-only approved solution formulation by the FDA for this medicine available in the US. Fresenius Kabi also sells Levothyroxine Sodium for Injection in the US market as a lyophilized powder in 100 mcg, 200 mcg and 500 mcg per 5 mL vial presentations.

John Ducker – president and CEO of Fresenius Kabi USA said: “Fresenius Kabi is pleased to continue to increase the number of products we offer to help care for patients with critical illnesses, including life-threatening thyroid conditions.

“This new liquid formulation of Levothyroxine promotes safe medication practices and operational efficiency by eliminating the need for reconstitution.”

  Fresenius Kabi, John Ducker, Levothyroxine Sodium Injection Solution, myxedema coma, severe hypothyroidism, USA